Ecotropic viral integration site 1 regulates the progression of acute myeloid leukemia via MS4A3‑mediated TGFβ/EMT signaling pathway

Jiang,Min; Zou,Xueqin; Huang,Wenhua

doi:10.3892/ol.2018.8890

Ecotropic viral integration site 1 regulates the progression of acute myeloid leukemia via MS4A3‑mediated TGFβ/EMT signaling pathway

Authors:
- Min Jiang
- Xueqin Zou
- Wenhua Huang
View Affiliations

Affiliations: Department of Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Internal Medicine, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, Yichang, Hubei 443003, P.R. China
Published online on: June 4, 2018 https://doi.org/10.3892/ol.2018.8890
Pages: 2701-2708

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute myeloid leukemia (AML) is a type of malignant tumor that is caused by malignant clone hematopoietic stem cells. The ecotropic viral integration site 1 (Evi1) is a zinc finger transcription factor, which is highly expressed in AML, and its expression level has been associated with poor prognosis of AML. Previous studies have indicated that Evi1 may regulate cell proliferation, differentiation and apoptosis by inhibiting the membrane‑spanning‑4‑domains subfamily‑A member‑3 (MS4A3) gene in AML. The aim of the present study was to investigate the role of Evi1 in the progression of AML. The results revealed that Evi1 was overexpressed in leukemia cells compared with normal T lymphocytes. MicroRNAs (miR)‑133 and ‑431 that target Evi1 were investigated, and it was observed that there was a low expression of miR‑431 in AML. The transfection of miR‑431 was able to decrease the promoter methylation levels of the Evi1 gene in AML cells. The transfection of miR‑431 also suppressed the migration and invasion of AML cells. The present study revealed that the transfection of miR‑431 mimic was able to downregulate MS4A3 expression in AML cells. Furthermore, the expression levels of transforming growth factor β (TGFβ) and epithelial‑to‑mesenchymal transition (EMT) markers fibronectin, α‑smooth muscle actin, and vimentin were downregulated following the transfection of miR‑431 in AML cells. The overexpression of MS4A3 was also able to suppress miR‑431‑mediated inhibition of the expression of TGFβ and EMT markers in AML cells. The addition of TGFβ inhibited the downregulation of EMT markers by transfection of miR‑431 in AML cells. The transfection of miR‑431 suppressed the migration and invasion of AML cells, which was also abolished by the addition of TGFβ. In conclusion, the results of the present study indicated that Evi1 may be a potential molecular target of leukemia therapy via MS4A3‑mediated TGFβ/EMT signaling pathway.

View Figures

View References

1	Varkaris A, Gunturu K, Kewalramani T and Tretter C: Acute myeloid leukemia after radium-223 therapy: Case report. Clin Genitourin Cancer. 15:e723–726. 2016. View Article : Google Scholar : PubMed/NCBI
2	Huang L, Wang SA, DiNardo C, Li S, Hu S, Xu J, Zhou W, Goswami M, Medeiros LJ and Tang G: Tetraploidy/near-tetraploidy acute myeloid leukemia. Leuk Res. 53:20–27. 2017. View Article : Google Scholar : PubMed/NCBI
3	Yamaguchi H: Gene mutations in acute myeloid leukemia. Rinsho Ketsueki. 57:2535–2542. 2016.(In Japanese). PubMed/NCBI
4	Uchida T, Hagihara M, Hua J and Inoue M: The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50. Leuk Res. 53:35–38. 2017. View Article : Google Scholar : PubMed/NCBI
5	Zhao SY, Tuerxun N, Chen R and Hao JP: Analysis of therapy and efficacy after remission of acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 24:1721–1724. 2016.(In Chinese). PubMed/NCBI
6	Liu C, Zhao L, Zhao J, Xu Q, Song Y and Wang H: Reduced ADAMTS-13 level negatively correlates with inflammation factors in plasma of acute myeloid leukemia patients. Leuk Res. 53:57–64. 2017. View Article : Google Scholar : PubMed/NCBI
7	Montewis A and Eveillard M: Acute myeloid leukemia with erythrophagocytosis indicative of KAT6A rearrangement. Blood. 128:3142016. View Article : Google Scholar : PubMed/NCBI
8	Pradhan AK, Halder A and Chakraborty S: Physical and functional interaction of the proto-oncogene EVI1 and tumor suppressor gene HIC1 deregulates Bcl-xL mediated block in apoptosis. Int J Biochem Cell Biol. 53:320–328. 2014. View Article : Google Scholar : PubMed/NCBI
9	Louz D, van den Broek M, Verbakel S, Vankan Y, van Lom K, Joosten M, Meijer D, Löwenberg B and Delwel R: Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice. Leukemia. 14:1876–1884. 2000. View Article : Google Scholar : PubMed/NCBI
10	Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW and Mills GB: Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res. 67:3074–3084. 2007. View Article : Google Scholar : PubMed/NCBI
11	Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS and Dutta A: Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer. Gynecol Oncol. 118:189–195. 2010. View Article : Google Scholar : PubMed/NCBI
12	Heller G, Rommer A, Steinleitner K, Etzler J, Hackl H, Heffeter P, Tomasich E, Filipits M, Steinmetz B, Topakian T, et al: EVI1 promotes tumor growth via transcriptional repression of MS4A3. J Hematol Oncol. 8:282015. View Article : Google Scholar : PubMed/NCBI
13	Gao JS, Zhang Y, Tang X, Tucker LD, Tarwater PM, Quesenberry PJ, Rigoutsos I and Ramratnam B: The Evi1, microRNA-143, K-Ras axis in colon cancer. FEBS Lett. 585:693–699. 2011. View Article : Google Scholar : PubMed/NCBI
14	Nayak KB, Kuila N, Das Mohapatra A, Panda AK and Chakraborty S: EVI1 targets ΔNp63 and upregulates the cyclin dependent kinase inhibitor p21 independent of p53 to delay cell cycle progression and cell proliferation in colon cancer cells. Int J Biochem Cell Biol. 45:1568–1576. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhang M, Xiao X, Liang Y, Peng M, Jiang Y, Xu Y and Gong G: Effect of methylation inhibitor on demethylation pattern of the PD-1 gene in promoter region and PD-1 expression in human T lymphocyte cell line. Zhong Nan Da Xue Xue Bao. Yi Xue Ban. 36:1163–1169. 2011.(In Chinese).
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Banerjee S, Yang S and Foster CB: A luciferase reporter assay to investigate the differential selenium-dependent stability of selenoprotein mRNAs. J Nutr Biochem. 23:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
18	Pham MH, Kondapalli N, Reckord CL and Foglesong PD: Interleukin-2 induces the activities of DNA topoisomerase I and DNA topoisomerase II in HuT 78 cells. Biochem Biophys Res Commun. 390:577–580. 2009. View Article : Google Scholar : PubMed/NCBI
19	Yue X, Zhao Y, Zhang C, Li J, Liu Z, Liu J and Hu W: Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction. Oncotarget. 7:3777–3790. 2016. View Article : Google Scholar : PubMed/NCBI
20	Humbert L, Ghozlan M, Canaff L, Tian J and Lebrun JJ: The leukemia inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human cutaneous melanoma. BMC Cancer. 15:2002015. View Article : Google Scholar : PubMed/NCBI
21	Noordermeer SM, Monteferrario D, Sanders MA, Bullinger L, Jansen JH and van der Reijden BA: Improved classification of MLL-AF9-positive acute myeloid leukemia patients based on BRE and EVI1 expression. Blood. 119:4335–4337. 2012. View Article : Google Scholar : PubMed/NCBI
22	Vázquez I, Maicas M, Cervera J, Agirre X, Marin-Béjar O, Marcotegui N, Vicente C, Lahortiga I, Gomez-Benito M, Carranza C, et al: Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica. 96:1448–1456. 2011. View Article : Google Scholar : PubMed/NCBI
23	Balgobind BV, Lugthart S, Hollink IH, Arentsen-Peters ST, van Wering ER, de Graaf SS, Reinhardt D, Creutzig U, Kaspers GJ, de Bont ES, et al: EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 24:942–949. 2010. View Article : Google Scholar : PubMed/NCBI
24	Weisser M, Haferlach C, Haferlach T and Schnittger S: Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: A report of four cases. Cancer Genet Cytogenet. 177:64–69. 2007. View Article : Google Scholar : PubMed/NCBI
25	Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF, Lübbert M, et al: High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 28:2101–2107. 2010. View Article : Google Scholar : PubMed/NCBI
26	Glass C, Wuertzer C, Cui X, Bi Y, Davuluri R, Xiao YY, Wilson M, Owens K, Zhang Y and Perkins A: Global identification of EVI1 target genes in acute myeloid leukemia. PloS One. 8:e671342013. View Article : Google Scholar : PubMed/NCBI
27	Kutok JL, Yang X, Folkerth R and Adra CN: Characterization of the expression of HTm4 (MS4A3), a cell cycle regulator, in human peripheral blood cells and normal and malignant tissues. J Cell Mol Med. 15:86–93. 2011. View Article : Google Scholar : PubMed/NCBI
28	Pan L, Ren F, Rong M, Dang Y, Luo Y, Luo D and Chen G: Correlation between down-expression of miR-431 and clinicopathological significance in HCC tissues. Clin Transl Oncol. 17:557–563. 2015. View Article : Google Scholar : PubMed/NCBI
29	Hu XT: TGFbeta-mediated formation of pRb-E2F complexes in human myeloid leukemia cells. Biochem Biophys Res Commun. 369:277–280. 2008. View Article : Google Scholar : PubMed/NCBI